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We studied with great enthusiasm the valuable 
comments of Dr. Khosravi
1
 et al, on our previously 
published article “Evaluation of Hepatitis B Infection 
Prevalence in Institutionalized Intellectually Disabled 
Children
2
”. They had three major concerns with the 
methods and findings of our article. Below we have 
responded to their concerns. 
Their first and major concern was the interesting 
finding of a higher frequency of HBV infection in 
children with a positive history of vaccination versus 
those with no such history and the authors stated 
“While there are studies in which the efficacy of 
neonatal HBV immunization has been proven. How 
the authors justify this finding?’’.  
Higher frequency of HBV infection in vaccinated 
individuals has not been previously reported, 
however the following observations have been 
reported in the literature:  
A) There are reports on the lower response of 
patients with Down syndrome to hepatitis B 
vaccination (as low as 17-29%)
3
. Low responders are 
at a higher likelihood of infection in comparison with 
non-vaccinated individuals.  
B) There are also reports on the shorter sustainability 




C) There are studies in which a higher frequency of 
vaccine escape mutations has been reported in 
vaccinated individuals.  
It is mentioned in the article that this is probably due 
to the infection by mutant HBV strains which could 
be resistant to immune response and vaccine. Indeed, 
some researchers have reported coexistence of HBs 
Ag and HBs Ab in HBV infected patients especially 
who received vaccine before
5
. For example, in one 
study in 1998 it has been shown that HBs Ag 
mutations accumulate with higher frequency in 
vaccinated than unvaccinated children
6
. Again, 
another study in 2006 it has been shown that in 
chronic hepatitis B patients, the coexistence of HBs 
Ag and HBs Ab is associated with an increase of 
HBs antigen variability, suggesting a selection of 
HBV immune escape mutants during chronic 
carriage
7
. Also the researchers suggested that the 
consequences of this selection process with regard to 
vaccine efficacy, diagnosis, and clinical evolution 
remain partially unknown. Also in another study in 
2007 it has been suggested that such HBs Ag-mutated 
HBV strains may not be fully sensitive to vaccine-
induced HBs Ab with the potential risk of vaccine 
failure including contamination of presumably 
protected vaccinated individuals
8
. On the other hand, 
the detection of such non-protective HBs Ab may also 
lead to misdiagnose chronic HBV infection if 
detection of HBsAg is not carried out simultaneously.  
Their second concern was that “the authors have not 
mentioned the sampling method of their study, which 
is the crucial factor of prevalence studies”. We admit 
that in ideal situations a random sampling of centers 
would have been the best option but practically 
regarding the disabilities of these children, ethical and 
legal issues impose a major limitation for blood 
sampling from these children. We sampled from 
centers with the cooperation of the staff and 
consequently parents or guardians of the children. We 
intentionally selected one center from each 
geographical location of Tehran (east, west, north, 
south and center) to cover the differences in economic 
and cultural differences of families living in different 
districts of Tehran. We sampled every eligible child in 
selected centers who had permissions of their parents 
or guardians. No recent study has been conducted on 
these vulnerable children for HBV infection. 
Therefore, the results of this study can be considered 
as the most representative available study until further 
studies would be available.  
The third concern of Dr. Khosravi et al., was that 
whether we enrolled children born before or after the 
national hepatitis B vaccination program as they 
quoted: “the time period in which the study was 
conducted has not been determined by the authors. 
Was it after or before distribution of a national 
vaccination program for hepatitis B?” We had 
mentioned in the article that all our participants were 
younger than 14 years. The reason for this age 
limitation in this study was based on internal roles of 
centers which held children younger than 14 years 
separates from older persons. Our study was 
performed during 2013-2014; therefore study 
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participants must have been born after 1999 which is 
well after the start of hepatitis B national vaccination 
program in Iran. 
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